CytomX Therapeutics, Inc. (CTMX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and thank you for standing by. Welcome to the CitumX Therapeutics CX2051 Phase 1 Interim Clinical Data Call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, Chris Ogden, CitumX's Chief Financial Officer. Please go ahead. Thank you. Good morning, and thank you for joining us. Before we begin, I would like to remind everyone that during this call we were making forward-looking statements. Because forward-looking statements relate to the future, they're subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filing with the SEC at sec.gov. We undertake no obligation to update any forward-looking statements whether as a result of new information, future developments, or otherwise. Earlier today, we issued a press release that includes a summary of our first quarter 2025 financial results and highlights recent progress at Cytomix. Additionally, this morning, we are excited to announce both positive interim phase one data for CX2051 and advanced colorectal cancer, as well as a $100 million financing with a leading group of healthcare investors. The focus of our call today will be the phase one data for CX2051. For details on the company's financial results and pipeline updates, we encourage everyone to read today's press releases and the associated materials, which have been filed with the SEC. Additionally, the press releases A recording of this call and our SEC filings can be found under the Investors in News section of our website. With me on the call today are Dr. Sean McCarthy, Sytomix's Chief Executive Officer and Chairman, and Dr. Wayne C...